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ABSTRACT
Objectives: Describe the rationale and protocol for
the Upper Limb International Spasticity (ULIS)-III
study, which aims to evaluate the impact of integrated
spasticity management, involving multiple botulinum
toxin A (BoNT-A) injection cycles and concomitant
therapies, on patient-centred goal attainment. Outline
novel outcome assessment methods for ULIS-III and
report initial evaluation data from goal setting in early
stages of the study.
Design: Large international longitudinal cohort study
of integrated upper limb spasticity management,
including BoNT-A.
Participants and setting: ULIS-III is a 2-year study
expected to enrol >1000 participants at 58 study
centres across 14 countries.
Interventions: The study design is non-interventional
and intended to reflect real-life clinical practice. It will
describe injection practices and additional treatment
strategies, and record clinical decision-making in a
serial approach to long-term spasticity management.
Outcome measures: ULIS-III will use a goal-
directed approach to selection of targeted
standardised measures to capture the diversity of
presentation, goals and outcomes. ULIS-III will
implement the Upper Limb Spasticity Index, a battery
of assessments including a structured approach to
goal attainment scaling (Goal Attainment Scaling—
Evaluation of Outcomes for Upper Limb Spasticity
tool), alongside a limited set of standardised
measures, chosen according to patients’ selected goal
areas. Concomitant therapy inputs, patient satisfaction
with engagement in goal setting, health economic end
points and health-related quality of life data will also
be captured.
Results of initial evaluation of goal quality:
Recruitment started in January 2015. By June 2015,
58 sites had been identified and initial data collected
for 79 patients across 13 sites in 3 countries. Goal
setting data were quality-checked and centres rated on
the basis of function-related and Specific, Measurable,
Achievable, Realistic, Timed (SMART) characteristics
of goal statements. Overall, 11/13 centres achieved
the highest rating (A++).
Conclusions: ULIS-III will provide valuable
information regarding treatment of and outcomes from
real-life upper limb spasticity management worldwide.
Trial registration number: NCT02454803; Pre-
results.
INTRODUCTION
Upper limb spasticity is a common and disab-
ling feature of neurological conditions that
affect the central nervous system.1–3 It may
induce pain, interfere with function or self-
Strengths and limitations of this study
▪ The Upper Limb International Spasticity
(ULIS)-III is the first large international longitu-
dinal cohort study to describe real-life clinical
practice and decision-making in spasticity man-
agement over a 2-year period of treatment.
▪ The structured approach to goal attainment
scaling linked to targeted standardised measures
will improve comparability of outcomes while
maintaining a patient-centred approach. This
approach may also have broader application for
outcome measurement in other areas of
healthcare.
▪ This study introduces new tools to capture
therapy interventions and spasticity-related
quality of life. While not yet fully validated, they
address areas that are poorly described in other
studies; ULIS-III will enable further validation.
▪ Training and proactive feedback on the standard
of goals set from an early stage in the study has
helped to ensure high-quality goal setting.
▪ This study represents a diverse sample of prac-
tice across four continents; however, the limited
number of subjects per centre (n=20–30) could
lead to a degree of selection bias.
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care and result in secondary complications such as
abnormal posture, contracture, pressure areas and
resultant deformity.1 Regardless of aetiology, active man-
agement is required to prevent these unwanted effects.1
There is an ever-growing body of evidence that loca-
lised injections of botulinum toxin A (BoNT-A) can be
effective in the management of upper limb spasticity.4
However, the diversity of individual goals for treatment
poses a challenge for the evaluation of outcomes from
treatment.1 5 6 Previous studies have identiﬁed the prin-
cipal goal areas of spasticity management, which include
improving active and passive function, reducing pain
and deformity, avoiding involuntary movements, improv-
ing mobility, and facilitating therapies such as postural
management, exercise, stretching and strengthening of
limbs, and splinting.7
Patient-centred goal setting is a fundamental guiding
principle of rehabilitation.8–10 However, communication
between clinicians and patients/caregivers to agree on
treatment goals and systematic documentation of goal
attainment are still not everyday practice for some
rehabilitation teams.11 12
Described originally in the 1960s by Kiresuk and
Sherman,13 goal attainment scaling (GAS) was intro-
duced in the context of upper limb spasticity manage-
ment in 200614 and has gained recognition over the past
decade as an effective method for capturing and quanti-
fying patient-centred goal achievement.6 15 However, it
does not provide directly comparable data; therefore,
standard outcome measures must be collected alongside
GAS to support comparison between different practices
and populations.16 Some authors have also called for
more standardised goals or ‘item banks’ to reduce the
variation in goal setting.17 Owing to this goal diversity,
the challenge is to incorporate standardised measures
that capture the diverse aims of treatment into a time-
effective approach that is practical for real-life clinical
practice.
The Upper Limb International Spasticity (ULIS)-III
study will aim to describe real-life clinical practice and
decision-making in integrated spasticity management
over a 2-year period, using a structured approach to GAS
that incorporates targeted standardised measures while
maintaining a patient-centred approach.
THE ULIS PROGRAMME AND THE EVOLUTION OF
OUTCOME MEASUREMENT
The ULIS programme consists of large international
observational studies investigating the use of BoNT-A
injections as part of an integrated spasticity management
strategy for the treatment of upper limb spasticity. The
overall aim of this programme is to describe real-life clin-
ical practice and to develop a common approach to
outcome measurement that could build into a core data
set for ongoing longitudinal evaluation, taking into
account the diversity of presentation and clinical
approaches to treatment.
The initial stage of the programme, ULIS-I,11 was a
cross-sectional survey conducted across 122 centres in 31
countries that documented the clinical proﬁles and
treatment goals and reported outcome evaluation in
adults receiving BoNT-A treatment for upper limb spasti-
city. The majority of clinicians (78%) reported setting
goals, but formal GAS was used in only 5% of centres.11
For the next stage of the programme, Turner-Stokes
et al18 concluded that goal attainment may provide an
acceptable common outcome measure for this context,
if it was applied consistently.
ULIS-II was an international observational study to
investigate goal attainment as a primary outcome follow-
ing a single BoNT-A injection cycle. It was conducted in
84 centres across 22 countries in the European Union,
Paciﬁc Asia, Eastern Europe and South America. A key
feature of ULIS-II was its development of a consistent
standard of goal setting and application of GAS in par-
ticipating centres, using the GAS-light method.16 The
approach was then used to quantify and characterise
patient-centred goals and to conﬁrm the validity of GAS
as an efﬁcient measure of patient outcome.18 The study
results showed that 80% of patients (n=363) achieved
their primary goals and that the use of an electronic
case report form (eCRF) was a feasible approach to data
collection for the ULIS study programme.5 The study
also conﬁrmed the validity of the GAS T-score as an
overall assimilation of primary and secondary goal attain-
ment. Clinicians were encouraged to continue to use
the standardised measures that they normally applied in
routine clinical practice. Although these were diverse,
some relationships emerged between the use of speciﬁc
measures and certain goals for treatment. For example,
visual analogue scales were commonly used alongside
GAS to record the reduction of pain symptoms or
improved ease of care.
ULIS-II formed the basis for development of a more
structured approach, framing goals around recom-
mended goal parameters for each goal area and using a
limited set of standardised measures from which the
subsets used were individually determined according to
priority goal areas. These reﬁnements to the GAS-light
approach were developed in a proof-of-principle study
before progression to the third stage of the ULIS pro-
gramme. They are described in more detail below.
Rationale for ULIS-III
Spasticity typically varies over time, both in its severity
and in the pattern of muscles affected. Its course may
ﬂuctuate, or follow a trajectory of recovery or progres-
sion, depending on the underlying condition, its phase
of development and treatment.1 Ongoing treatment may
include further injections of BoNT-A into the same or
different muscles, physical interventions (eg, splinting,
task practice or exercise, functional electrical stimula-
tion), or the use of other antispasmodic medications.1
Longitudinal data are therefore needed to record
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progress over time and to capture clinical decision-
making along the care pathway.
ULIS-II provided an overview of how treatment goals
and outcome measures were applied in a single cycle of
treatment with BoNT-A. However, it did not provide
insight into the changing course of treatment over time.
It recorded concomitant treatments in terms of the
number of therapy sessions, but did not provide infor-
mation on their content. Nor did it attempt to capture
information on quality of life or health utility in relation
to spasticity management.
The present study, ULIS-III, will expand the patient
cohort to evaluate integrated spasticity management that
includes multiple BoNT-A treatment cycles and con-
comitant therapies, as delivered in real-life clinical prac-
tice. It will implement a novel approach to outcome
measurement using patient-centred goal setting and
GAS alongside standardised validated outcome mea-
sures, in a generalisable sample, recorded longitudinally
over a 2-year period.
NOVEL ASSESSMENT METHODS
ULIS-III will use the Upper Limb Spasticity Index
(ULS Index) to record patient-centred goals and stan-
dardised outcomes directed by priority goal areas. This
is a battery of assessments designed to capture the diver-
sity of presentation, goals and outcomes inherent in
populations of patients with upper limb spasticity, while
targeting measurement on the priority areas of treat-
ment for that individual. While the goal-directed
approach to selection of targeted standardised measures
is novel in this context, the measures themselves are well-
validated tools and are suitable for use in routine
practice.
ULIS-III will also employ some new tools including:
▸ The Upper Limb Focal Spasticity Therapy Recording
Schedule (ULSTR), which records the number, dur-
ation and types of therapies related to speciﬁc goals;
▸ The Spasticity-Related Quality-of-Life Tool (SQoL-6D),
which records health utility data and is designed spe-
ciﬁcally to assess aspects of quality of life that are likely
to be affected by spasticity.
Although these new instruments have not been fully
validated, they address areas that have been poorly docu-
mented in previous studies and for which currently avail-
able tools are deﬁcient.
Figure 1 summarises the process for application of
measures in ULIS-III.
The ULS Index
The ULS Index is a battery of assessments that can be
used to evaluate both patient-rated and clinician-rated
components of outcome measurement in upper limb
spasticity.
The three main components of the ULS Index are as
follows (details provided in table 1):
1. Severity of presentation and confounders to recovery,
including:
▸ Demographics;
▸ Distribution and severity of spasticity and soft
tissue contractures;
▸ Severity of impairment
– Local to upper limb (eg, motor control, sensory
loss, neglect),
– General (eg, cognitive, behavioural, communi-
cative, mood).
2. Individual GAS using a structured approach,
including:
– Goal Attainment Scaling—Evaluation of Outcome
for Upper Limb Spasticity (GAS-eous): Speciﬁc,
Measurable, Achievable, Realistic and Timed
(SMART) goal setting supported by targeted
standard measures according to goal areas;
– Patient satisfaction with and engagement in goal
setting.
Figure 1 Process of application
of measures in the ULIS-III study.
BoNT-A, botulinum toxin A;
GAS-eous, Goal Attainment
Scaling—Evaluation of Outcome
for Upper Limb Spasticity;
ULIS-III, third study in the Upper
Limb International Spasticity
programme.
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3. A limited set of standardised measures
▸ The measures applied are determined by the goal
areas, so a standard measure is rated ONLY
when that category is one of the goals for
treatment.
Standardised measures in the ULS Index
Standardised outcome measures were selected on the
basis that they were supported by published evidence of
validity and were already used in clinical practice by
centres in ULIS-II.
▸ The Modiﬁed Ashworth Scale (MAS), which reports
variations in muscle tone during ﬂexion and exten-
sion, measures severity of spasticity.19 MAS was
selected over other spasticity measures as it was
demonstrated in the ULIS-I and ULIS-II studies to
be the most widely used tool in routine clinical
practice.5 18
▸ The Upper Limb Spasticity-adapted version of the
Neurological Impairment Scale (ULS-NIS) measures
severity of functional impairment,20 and was used in
ULIS-II.
▸ The Numbered Graphic Rating Scale (NGRS) and
Scale of Pain Intensity (SPIN) are visual analogue
and verbal rating scales for evaluating symptoms
including pain, ease of care, ease/difﬁculty in per-
forming a task and sleep quality, among others.22
▸ The Associated Reaction Rating Scale (ARRS) is used
to measure involuntary movements,23 for example,
those associated with walking.
▸ The Arm Activity (ArmA) measure is a standardised
scale for determining active and/or passive function.24
▸ The Functional Ambulation Category (FAC)25 and
the 10 m walk test record walking ability.
The GAS-eous tool
The GAS-eous tool was designed to provide a structured
framework for the application of GAS alongside standar-
dised measures in the context of upper limb spasticity.26
Its development was based on a previous secondary ana-
lysis7 that evaluated goals set for the treatment of upper
limb spasticity (n=696 primary or secondary goals)
according to GAS across four single-centre and multi-
centre studies.6 14 27 28 GAS for these studies was applied
as described by Turner-Stokes,16 an adaptation of the
method published by Kiresuk and Sherman.13 Goal deﬁ-
nitions were extracted from these previous studies, classi-
ﬁed and then mapped onto the WHO International
Classiﬁcation of Functioning, Disability and Health
(WHO ICF).29 The results highlighted two domains and
six key goal areas, which were incorporated into the
GAS structure, along with their associated outcome para-
meters, to form the GAS-eous tool, as shown in table 2.
The ﬁrst domain centres on ‘symptoms and impair-
ment’ and includes spasticity-related pain relief, reduc-
tion of involuntary movements and improved/
maintained range of movement to prevent contractures
and deformity. The second domain centres on ‘activities
and function’ and includes passive function (making it
Table 1 Components of the ULS Index
ULS Index Rated by clinician Rated by patient/carer
A. Severity and confounders (history and
examination)
Demographics NA
Distribution of spasticity
Severity of spasticity (MAS)19
Severity of impairment (ULS-NIS)20
Soft tissue contractures (loss of
range)
NA
B. Goals for treatment GAS-eous tool: SMART goals negotiated between patient and team with
associated measurement parameters within each chosen goal area
Patient engagement in goal
setting21
Patient satisfaction with goals21
C. Standardised measures—applied according
to the CHOSEN GOAL AREAS for treatment
Symptoms NA Pain rating/10 (NGRS or SPIN)22
Involuntary movements ARRS23 NA
Function: passive and active NA ArmA: passive and active
function24
Ease of caring for limb (NGRS)
Mobility FAC25
10 m walk (speed)
NA
Global benefits Global benefit scale (−2 to +2) Global benefit scale (−2 to +2)
ArmA, Arm Activity measure; ARRS, Associated Reaction Rating Scale; FAC, Functional Ambulation Category; GAS-eous, Goal Attainment
Scaling—Evaluation of Outcome for Upper Limb Spasticity; MAS, Modified Ashworth Scale; NA, not applicable; NGRS, Numbered Graphic
Rating Scale; SMART, Specific, Measurable, Achievable, Realistic and Timed; SPIN, Scale of Pain Intensity; ULS Index, Upper Limb
Spasticity Index; ULS-NIS, Neurological Impairment Scale - Adapted for Upper Limb Spasticity.
4 Turner-Stokes L, et al. BMJ Open 2016;6:e011157. doi:10.1136/bmjopen-2016-011157
Open Access
group.bmj.com on September 27, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
easier to care for the affected upper limb), active func-
tion (using the affected limb for everyday tasks or activ-
ities) and improving mobility (eg, maintaining balance,
improved gait quality/efﬁciency). A small number of
patients identiﬁed goals in other areas such as improv-
ing body image (cosmesis) and facilitating therapy.7
For the GAS-eous method, the patient and/or their
family identify one primary and up to two secondary
Table 2 Classification of goals and measurement parameters that provide the framework for the GAS-eous tool
Key goal areas Goal definition
Examples of recommended goal
parameters
Domain 1. Symptoms/impairment
Pain/discomfort (b280, b780) Spasticity-related symptoms
▸ Pain (b280)
▸ Discomfort due to stiffness
(b780)
Rating/10 (recorded in whole numbers using
a verbal rating scale or a numbered graphic
rating scale)
Involuntary movements (b755, b760,
b765)
Unwanted involuntary movements
during use of other limbs
▸ Associated reactions (b755,
b760)
▸ Spasms or dystonic movements
(b765)
Carry angle of elbow/height of hand up torso
during walking
Spasm frequency (number per day/night)
Contracture prevention or
improvement (b710, b735)
Improving range of movement
(b735)
▸ Prevention of contractures/
deformity (b710)
▸ Splint application or tolerance
Percentage normal joint range (eg, 25%,
50%, 75%)
Ease of application (rating/10) or tolerance
(hours per day)
Domain 2. Activities/function
Passive function (care tasks)
(d510, d520)
Ease of caring for the affected limb,
for example:
▸ Maintaining hygiene of hand,
elbow, axilla (b510)
▸ Maintaining skin integrity, cutting
fingernails (d520)
▸ Dressing and positioning the
limb, splint application
Ease of care rating/10 or time to complete
care tasks
Rating on ArmA—passive subscale
Active function
▸ Using the affected limb
(d430, d440, d445)
Active motor tasks, for example:
▸ Reaching, grasp/release,
holding/manipulating objects
(d445)
▸ Fine dexterity (d440) and lifting/
carrying objects (d430)
Ability or time taken to complete defined task
Rating of control or ease of movement/10
▸ Functional purpose (d500,
d510, d540, d550, d560,
d630, d640, d850, d920)
Activities of daily living
▸ Personal: eating/drinking (d550,
d560), self-care (d500, d510,
d540)
▸ Extended activities of daily living
(d630, d640)
▸ Occupational: work (d850) or
recreation (d920)
Ability or time taken to complete defined task
Rating on ArmA—active subscale
Mobility (d415, d420, d450) Improved mobility
▸ Ease of transfers (d420),
balance, standing (d415)
▸ Walking (d450)
Time taken (eg, timed up and go)
Gait speed/endurance
Patient confidence, safety, frequency of trips/
falls
Other
Cosmesis/body image Patient’s perception of body image,
aesthetic appearance
Patient satisfaction rating/10
Therapy facilitation Team’s perception of interference
with therapy
Team rating/10
Domains and key goal areas were identified in a multicentre analysis.7 The WHO International Classification of Functioning, Disability and
Health codes are indicated.29 The recommended goal parameters may be used to define SMART goals within the selected areas.
ArmA, Arm Activity measure; GAS-eous, Goal Attainment Scaling—Evaluation of Outcome for Upper Limb Spasticity; SMART, Specific,
Measurable, Achievable, Realistic and Timed.
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goals for treatment. Each goal is classiﬁed into one of
the six key goal areas. SMART goal statements are then
agreed on between the team and the patient/family,
using one or more of the recommended goal para-
meters (wherever possible) to frame the SMART goal
statement (see table 2).
The selected goal areas determine the standardised
measures used alongside GAS within the ULS Index.
Baseline and outcome GAS scores are recorded using
the verbal rating scale in the GAS-light model.16 This
translates into the ﬁve-point rating scale (−2 to +2) and
goal scores are combined using the GAS formula to
derive an overall T-score using a standard formula.13
The GAS-eous method offers several potential ad-
vantages over traditional GAS. The more structured
approach is designed to streamline goal setting in busy
clinical settings, thus reducing the time taken to apply
GAS. In addition, targeted selection of relevant standar-
dised outcome measures reduces the time that would
otherwise be spent recording numerous, less relevant
measures. Importantly, GAS-eous retains the individua-
lised nature of patient-centred goal setting focused on
the patient’s own priorities.
GAS is not just a measurement tool. Evidence suggests
that engagement of patients in their own goal manage-
ment can be an effective intervention in its own right.30
Alongside GAS-eous, ULIS-III will record patient engage-
ment in goal setting and their satisfaction with the goals
using six-point Likert scales designed speciﬁcally for this
purpose.21
Further information about the GAS-eous and
associated tools may be found at the following
websites: http://www.kcl.ac.uk/lsm/research/divisions/
cicelysaunders/resources/tools/gas-eous.aspx; http://
www.kcl.ac.uk/lsm/research/divisions/cicelysaunders/
resources/tools/gas.aspx.
The ULSTR
The ULSTR, a novel instrument designed for the ULIS
programme, will record the physical interventions used
to manage upper limb spasticity, and relate concomitant
therapies to speciﬁc goal achievement. These interven-
tions may include splinting, shoulder supports/slings,
serial casting, upper limb positioning, stretches, neuro-
muscular electrical stimulation, strength training or task
training. The ULSTR records both the type and intensity
of interventions provided to patients. It was developed as
part of the proof-of-principle study for ULIS-III as there
was no tool available for relating patient goals to the
concomitant therapies required for their achievement.
The ULSTR is still undergoing full evaluation but will be
used in ULIS-III as part of that process.
The ULSTR tool can be found at the following website:
www.kcl.ac.uk/lsm/research/divisions/cicelysaunders/
resources/tools/Upper-Limb-focal-Spasticity-Therapy-
Recording-schedule-(ULSTR).aspx.
The Spasticity-Related Quality-of-Life Tool
SQoL-6D is another novel tool that was designed for the
ULIS programme to further assess the quality of life ben-
eﬁts of BoNT-A treatment in patients with upper limb
spasticity. It is a self-completed six-item questionnaire
intended to evaluate quality of life in relation to upper
limb spasticity within the key goal areas deﬁned for GAS-
eous (table 2).
SQoL-6D was developed because generic health utility
measures, such as the Short Form-36 Health Survey and
Assessment of Quality of Life instrument, have proven
insensitive for evaluating change in quality of life with
focal intervention for upper limb spasticity.15 31
SQoL-6D is still undergoing development and evaluation
in its original language (English) and has not yet been
translated into other languages. ULIS-III will include
piloting of the self-completed SQoL-6D in the subset of
native English-speaking countries (Australia and the
USA). It will be applied in this subgroup alongside the
EuroQol Five Dimensions, Five Levels (EQ-5D-5L), a
standardised generic health utility measure describing
outcomes in ﬁve domains: mobility, self-care, usual activ-
ities, pain or discomfort, and anxiety/depression.32 33
The SQoL-6D tool can be found on the follow-
ing website: www.kcl.ac.uk/lsm/research/divisions/
cicelysaunders/resources/tools/The-Spasticity-Related-
Quality-of-Life-Tool-(SQoL-6D).aspx.
ULIS-III STUDY PROTOCOL: METHODS AND DESIGN
The overall aims of ULIS-III are to describe real-life clin-
ical practice and outcomes in the context of integrated
upper limb spasticity management and to gain insights
into which patients do best with which approaches to
treatment over time. The trial protocol is available on
ClinicalTrials.gov.34
Study objectives
The primary objective is to assess the attainment of
patient-centred and function-related goals following
repeated BoNT-A injections (where used) and alongside
integrated upper limb spasticity management in real-life
settings over a 2-year period. The primary outcome is
the cumulated GAS T-score, deﬁned as the mean of the
individual GAS T-scores for all cycles per patient.
Secondary objectives are to:
▸ Describe the baseline characteristics of the study
population, including demographics, duration and
pattern of spasticity, and confounders (eg, severity of
impairment).
▸ Describe injection practices and additional treatment
strategies, and record clinical decision-making in the
serial approach to spasticity management over time.
▸ Assess the attainment of patient-centred goals by goal
area following each cycle of BoNT-A injections and
overall attainment after repeated cycles, alongside
standardised measures of symptoms, impairment, dis-
ability (activity limitation) and participation selected
Open Access
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on an individual basis according to the goals for
treatment.
▸ Describe and quantify concomitant therapy use and
explore its relationship with goal attainment.
▸ Carry out a substudy of ULIS-III that will assess
change in quality of life among a subpopulation of
patients in Australia and the USA using generic and
condition-speciﬁc instruments.
Study design and setting
ULIS-III is a 2-year, international, multicentre, observa-
tional, prospective, longitudinal cohort study that is
expected to enrol over 1000 participants in 58 study
centres across 14 countries. The study design is non-
interventional and intended to reﬂect real-life clinical
practice.
Study centres will be located in countries with market-
ing authorisation for at least one BoNT-A preparation
for upper limb spasticity treatment. In addition, all eli-
gible study centres must aim to follow the UK national
consensus guidelines for the use of BoNT-A in the man-
agement of spasticity,1 and be able to collect data using
GAS-eous and the tools included in the ULS Index.
The investigators’ decision to prescribe BoNT-A must
be taken prior to and independently from their decision
to enrol the patient, as well as in accordance with
routine clinical practice at the study site concerned.
Ethics and dissemination
ULIS-III is conducted in compliance with the
Declaration of Helsinki, the Council for International
Organizations of Medical Sciences International Ethical
Guidelines for Epidemiological Studies35 and the guide-
lines for Good Pharmacoepidemiology Practices.36
Ethics approval will be sought at each site according to
local legislation. All patients must provide written
informed consent to participate in the study and to
allow their medical data to be collected and analysed, or
patient participation must be validated in accordance
with local policy/guidelines.
An electronic data capture system (Viedoc 4, PCG
Solutions AB, Uppsala, Sweden) will be used by the
investigators to collect data in an electronic format; data
will then be anonymised and transmitted to the sponsor
for analysis.
Since ULIS-III is a non-interventional study, safety data
will not be collected or analysed; however, standard regu-
lations for reporting treatment-related spontaneous
adverse events still apply within each country.
Study results will be presented at international meet-
ings and published in peer-reviewed journals.
Recruitment
Patients are required to meet the following enrolment
criteria:
▸ Adults, ≥18, 20 or 21 years of age dependent on local
legislation, with upper limb spasticity, in whom a deci-
sion has already been made to inject BoNT-A.
▸ Patients may or may not have previously received
BoNT-A injections.
▸ No previous participation in any other interventional
clinical study of upper limb spasticity within the
12 weeks prior to their inclusion visit; no previous
inclusion and subsequent withdrawal from this study.
A maximum of 20–30 patients per centre will be
included. In order to avoid selection bias, patients in
each centre will be recruited consecutively or according
to a regular pattern.
Treatment
In order to replicate real-life settings, clinicians will
make decisions regarding the type of BoNT-A prepar-
ation (Dysport (Ipsen Pharma, Paris, France), Botox
(Allergen, Inc, Irvine, California, USA), Xeomin (Merz
GMBH & Co. KGaA, Frankfurt, Germany) or other)
doses used, frequency of injection, target muscles for
injection, number of injection points and volume
injected per point on an individual patient basis. These
decisions will be made according to usual clinical prac-
tice or in accordance with the current local summary of
product characteristics.
Although recruitment to the study is triggered by a
clinical decision to inject BoNT-A, thereafter patients
will be followed up regardless of whether they have
further injection cycles or not. Patients will undergo
assessments and receive further BoNT-A injections at
visits arranged according to the investigator’s practice.
End-of-assessment visits, or phone interviews for those
participants who stopped treatment during the study,
will be conducted no more than 24 months after the
initial BoNT-A injection.
Goal setting and goal attainment assessment
Goal setting and goal attainment assessment will be
implemented using the GAS-eous tool,5 18 as described
above. Procedures to support a high standard of goal
setting are detailed below.
Goal attainment will be recorded on a ﬁve-point
numerical scale (range −2 to +2) and goal scores com-
bined to give an aggregated T-score at each visit, using a
standard formula.13 Overall goal attainment will be
assessed using the cumulated GAS T-score.
Outcome assessments
The outcome measures for ULIS-III will primarily be
captured using the ULS Index together with the ULSTR
and the two health utility measures (the SQoL-6D and
the EQ-5D-5L, native English-speaking subgroup only),
as described above. Table 3 summarises how they will be
applied throughout the study.
For the purposes of comparison with other studies,
ULIS-III will also record the Disability Assessment Scale
(DAS),37 deﬁning the Principal Target for Treatment
(PTT) at each visit.
As part of the ULIS Index, a global assessment of ben-
eﬁts will be performed by the investigator as well as the
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patient and/or caregiver, with changes from previous
visits classiﬁed as: much worse (−2), worse (−1), no
change (0), some beneﬁt (+1) or great beneﬁt (+2).
Health economic evaluation
Healthcare resource utilisation, including direct clinical
costs, indirect costs associated with spasticity and con-
comitant medications, will be assessed at baseline and at
every subsequent visit. These will include assessment of
changes in concomitant treatments, such as medications
associated with spasticity and pain, changes in employ-
ment status and maintenance of healthcare, for
example, nurse or caregiver. ULSTR data will be used to
determine healthcare resource use associated with
upper limb spasticity-related physical therapy.
Utility data (quality-adjusted life-years (QALYs)) for
the subgroups of patients in native English-speaking
countries will be derived using data from the EQ-5D-5L
and SQoL-6D assessment tools.
Study schedule and assessments
The nature and timing of patient assessments will be in
accordance with routine clinical practice at the individ-
ual study centres. It is expected that some patients will
Table 3 Summary of outcome measures
Outcome Measure used
Primary outcome
Patient-centred goal attainment Cumulated GAS T-score, defined per patient as the mean of the
individual GAS T-scores for all cycles through 24 months (in
predefined goal categories) derived using:
▸ GAS-eous tool
▸ Goal-related standardised measures within the ULS Index
Secondary outcomes
Baseline clinical characteristics
▸ Muscle tone ▸ MAS
▸ Severity of different aspects of impairment in both
upper limbs in patients with neurological damage
▸ ULS-NIS
Treatment administration
▸ Documentation of real-life injection practices
▸ BoNT-A preparation INN
▸ Dose
▸ Date(s) of injection(s)
▸ Injection points and injection guidance (EMG, ES, US)
▸ Reasons for any changes to BoNT-A injection practice
Concomitant therapies (eg, specific interventions by
physiotherapists and occupational therapists)
ULSTR
Patient-centred goal attainment over time by goal area Cumulated GAS T-score of all goals assessed within each goal
area
Attainment of treatment goals after each cycle of BoNT-A
injections
Changes in the GAS T-score for each injection cycle
Percentage achievement of treatment goals per goal
area
Documented overall and per injection cycle
Evolution of goal changes across the study Recorded alongside changes from baseline in the standardised
outcome measures
Correlations of patient-centred goals and related
standardised rating scales
GAS-eous and standardised outcome measures selected
according to the goals for treatment within the ULS Index (NGRS
or SPIN, ArmA, FAC, ARRS)
Change in disability ▸ Change from baseline in the four domains of DAS (hygiene,
dressing, limb position and pain)
▸ PTT will be defined at each visit, based on one of the four DAS
domains
▸ Change from baseline/previous visit in the PTT
Global assessment of benefits By investigator and caregiver/patient
Change in quality of life* ▸ EQ-5D-5L
▸ SQoL-6D
*Only in subpopulations of patients in the USA and Australia.
ArmA, Arm Activity measure; ARRS, Associated Reaction Rating Scale; BoNT-A, botulinum toxin A; DAS, Disability Assessment Scale; EMG,
electromyography; EQ-5D-5L, EuroQol Five Dimensions, Five Levels; ES, electrostimulation; FAC, Functional Ambulation Category; GAS,
goal attainment scaling; GAS-eous, Goal Attainment Scaling—Evaluation of Outcomes for Upper Limb Spasticity; INN, international
non-proprietary name; MAS, Modified Ashworth Scale; NGRS, Numbered Graphic Rating Scale; PTT, principal target of treatment; SPIN,
Scale of Pain Intensity; SQoL-6D, Spasticity-Related Quality-of-Life Tool; ULS Index, Upper Limb Spasticity Index; ULS-NIS, Upper Limb
Spasticity-adapted version of the Neurological Impairment Scale; ULSTR, Upper Limb Focal Spasticity Therapy Recording Schedule; US,
ultrasound.
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discontinue follow-up within the 2-year period, as spasti-
city can be a self-limiting condition. End-of-study visits or
telephone interviews will be conducted 24 months after
recruitment to ascertain the patient’s condition and
reasons for discontinuing follow-up, if this was the case.
All primary and secondary goals and outcome assess-
ment data will be documented in eCRFs at each visit. To
ensure data consistency and accuracy, all amendments to
eCRF data once entered will be automatically tracked
and a reason for change will be required.
Planned statistical analysis
All statistical evaluations will be performed using the
Statistical Analysis System (SAS V.9 or later; SAS
Institute, Inc, Cary, North Carolina, USA) according to a
preplanned analysis strategy. No formal treatment com-
parisons will be made; however, results will be reported
descriptively with 95% CIs and p values presented for
exploratory purposes only. A p value of <0.05 will be
considered to indicate statistical signiﬁcance.
Sample size calculation
Sample size was calculated on the basis of detecting an
effect size of 0.5 in the primary end point of cumulated
GAS T-score across the full study. Assuming a type I
error of 5% (two-sided) and a power of ≥90%, ≥800
patients will allow comparisons between seven goal areas
based on cumulated GAS T-scores. This will also allow
comparisons with ≥80% power in the case of an unba-
lanced distribution of up to 3:1 between goal areas.
Assuming a 20% dropout rate, the target recruitment
number is ≥1000 patients.
Effectiveness evaluation
The cumulated GAS T-score, deﬁned as the mean of the
GAS T-scores for each individual patient for all visits
over the 24-month study period, will be presented
descriptively using summary statistics.
Cumulated GAS T-scores, calculated by goal area, will
be compared descriptively, using an analysis of variance
model and individual pairwise comparisons, to assess the
relative attainment of goals between the different goal
areas.
The correlation between goal attainment and change
from baseline (visit 1) in the associated standardised
measures will be assessed using Spearman’s rank correl-
ation coefﬁcients. The observed correlation coefﬁcients
will be assessed for difference from zero using a permu-
tation test and p values will be presented. All other sec-
ondary end points will be reported descriptively.
Exploratory analyses
The relationship between primary outcome (cumulated
GAS T-score) and intervention programme (BoNT-A
and physical therapy interventions) will be explored
descriptively. A stepwise linear regression model will be
used to identify prognostic factors for response, which is
deﬁned as an improvement from baseline GAS T-score
of at least +10 points. In addition, descriptive analyses
will be carried out to evaluate and describe any possible
country and centre effects.
Health economics analysis
Estimated direct and indirect healthcare costs associated
with upper limb spasticity will be presented descriptively
based on assigning unit costs derived from established
sources of unit cost data to the healthcare resources
used. The sources of unit cost data will be determined
at a data review meeting. Cost-effectiveness ratios for
cost per response will be based on patients’ Disability
Assessment Score achievement, which is deﬁned as an
improvement of ≥1 point in the DAS score in the princi-
pal target of treatment at the end of the study compared
with visit 1, with separate analyses performed for each
domain. GAS outcomes will also be evaluated for these
subgroups. In addition, analyses will be performed on
the US and Australian subgroups to evaluate cost per
QALY and cost-utility.
Trial status
Recruitment began in January 2015 and patient partici-
pation duration is 2 years. It is estimated that the enrol-
ment target of 1000 patients will be achieved by
December 2016 and the ﬁnal analysis of patient data is
expected to be completed in the ﬁrst quarter of 2019.
QUALITY EVALUATION OF GOAL SETTING
The validity of GAS depends on a high standard of goal
setting and documentation of SMART goal statements.
Goals should be centred on improvement at the level of
function, as opposed to impairment, as deﬁned by the
WHO ICF.29
In ULIS-II, an interim validation process was un-
dertaken part-way through recruitment to ensure that
clinicians were setting SMART function-related goals in
accordance with the training.18 Goal statements were
examined on a centre-by-centre basis and investigators
were blinded to country and centre. Statements were
assessed on two criteria: the WHO ICF domain for
function (A, B, C); and the quality of the SMART descrip-
tion (− to ++), as previously described.18 It was accepted
that, for some patients, goal statements would be
impairment-related (eg, prevention of contractures).
However, investigators expected that at least some goals
from each centre would be related to function. The clini-
cians received feedback and had the opportunity to
improve the quality of their goal statements for patients
who had not yet returned for their second visit. This led
to documented improvement, but by the end of the study
only 25% of centres achieved the top rating (A++).18
Part of the rationale for development of the GAS-eous
tool was to improve the quality of goal setting, and the
recruiting centres (many of which also recruited for
ULIS-II) have undergone further training for ULIS-III.
Goal reviews, validation and feedback by the Steering
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Group will also be conducted at more frequent intervals
throughout the recruitment phase to facilitate a high
standard of goal setting.
Participant recruitment was initiated in January 2015.
By the ﬁrst goal review in June 2015, 58 sites had been
selected globally, over half had received training on the
study and 15 sites had started recruitment across ﬁve
countries, including Australia, Austria, France, Russia
and Poland. Initial patient data have been collected for
79 patients across 13 sites in three countries. Of these 79
patients, 42 set primary goals only, 24 also set one second-
ary goal and 13 set two secondary goals in addition to a
primary goal. Goal setting data were quality checked and
centres were given a rating based on the WHO ICF and
SMART guidelines, as described above.18 As shown in
table 4, 11/13 centres achieved the highest rating (A++).
Goals were organised into two domains and subdi-
vided into six key goal areas. The most common areas
for primary goals were passive function (30/79 (38.0%))
followed by active function (17/79 (21.5%)) and pain
(17/79 (17.7%)). Although the percentages varied
slightly, the total 129 goals, including secondary goals,
represented a broadly similar pattern. Only two primary
goals did not ﬁt into these six key goal areas—these
addressed improvement of cosmesis (perception of body
image) and the facilitation of therapy. These ﬁndings
provide support for the validity of the goals classiﬁcation
that underpins the GAS-eous tool.
DISCUSSION
The ULIS programme sets in train a methodology that
is practical for use in routine clinical practice and in
future studies. This methodology will enable studies to
expand their clinical data set to one of sufﬁcient size to
elucidate important ﬁndings, including which patients
are most likely to beneﬁt from what types of treatment
and how best to capture the outcomes.
ULIS-III will build on previous studies that have used
goal attainment to evaluate outcomes from upper limb
spasticity interventions.5 6 38 It will expand the patient
cohort and capture the beneﬁts of treatment in real-life
clinical practice over several treatment cycles. ULIS-III
will use a more structured approach to outcome meas-
urement incorporating both GAS and standardised mea-
sures in a targeted way that is feasible to implement in
clinical practice. In addition, it will assess the wider ben-
eﬁts of BoNT-A treatment for upper limb spasticity by
evaluating economic and quality of life data, as well as
concomitant therapies.
Initial data from the inclusion visits of 79 patients
across 13 centres in three countries provide support for
the validity of the goals classiﬁcation that underpins the
GAS-eous tool, and demonstrate a high standard of goal
setting in the majority of centres.
Strengths and limitations
The strengths of the ULIS-III approach include the wide
international representation of participating centres,
which will capture the experience of clinicians from
around the globe, ensuring the generalisability of
results. The use of patient-centred goal setting and GAS
in ULIS-III will enable the assessment of outcomes that
are important to the patient and/or their family while
maintaining realistic expectations for the outcome. In
addition, the structured approach to GAS in parallel with
standardised measurement may improve the comparabil-
ity of results across different settings. Moreover, a high
standard of goal setting is supported by a comprehensive
GAS training programme and interim goal reviews.
However, there are recognised limitations of the
ULIS-III approach. Recruitment is restricted to 20–30
patients per centre, which may introduce some selection
bias through under-representation of less common pre-
sentations of spasticity. In addition, the use of tools that
are still undergoing evaluation (ULSTR and SQoL-6D)
means that the data generated from these will be less
robust. However, they may help to ﬁll gaps in knowledge
for which no prevalidated tools exist currently.
Despite the recognised limitations, ULIS-III will
provide a unique and important set of information
regarding treatment with and outcomes from BoNT-A in
real-life management of upper limb spasticity worldwide.
The present methodology will help to ensure credibility
of results from ULIS-III, and will also underpin future
studies and inform other clinical trials and cohort
studies in this context.
The ULIS Programme Steering Group
▸ Expert clinicians: LT-S (clinical lead), SA, KF, JJ
▸ Ipsen staff: JB, PM, Hugues Berard
Table 4 Goals set and centre ratings at visit 1
Country/
centre ID
Number of
primary
goals set
Number of
secondary
goals set
Centre
rating
1/4 1 0 Not entered
at time of
data
extraction
1/5 1 2 A++
1/6 5 5 A++
1/8 1 0 A++
2/1 4 0 A−
2/2 15 5 A++
2/4 24 2 A++
3/1 4 8 A++
3/2 12 15 A++
3/3 2 2 A++
3/5 2 3 A++
3/6 2 3 A++
3/7 6 5 A++
Rating: A, Some goal statements contain reference to functional
activities at the level of disability or participation; ++, there is a
specific, measurable, achievable, realistic and timed goal
description, sufficiently detailed and specific to make an accurate
goal attainment scaling rating; −, no clear goal description.
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